ArticleNature medicine2020
Polygenic architecture informs potential vulnerability to drug-induced liver injury.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 78 citations in OpenAlex.
- Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods.Nature communications · 2022Trial
- Induced pluripotent stem cells from discovery to translation.Nature medicine · 2026Review
- Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.EBioMedicine · 2026Article
- The evolving landscape of pharmacogenomics: Current achievements and future directions.Pharmacological reviews · 2026Review
- Advances in Cytotoxicity Testing: From In Vitro Assays to In Silico Models.International journal of molecular sciences · 2025Review
- Modeling antithymocyte globulin-induced microvasculopathy using human iPSC-derived vascularized liver organoids.Cell reports. Medicine · 2025Article
- The Use of Organoid Cultures in Advancing Nutrition Research.Advances in nutrition (Bethesda, Md.) · 2025Review
- Comprehensive analysis of high-throughput transcriptomics to distinguish drug-induced liver injury (DILI) phenotypes.Archives of toxicology · 2025Review
- Advancing hepatotoxicity assessment: current advances and future directions.Toxicological research · 2025Review
- Current hPSC-derived liver organoids for toxicity testing: Cytochrome P450 enzymes and drug metabolism.Toxicological research · 2025Review
- Polygenic modelling and machine learning approaches in pharmacogenomics: Importance in downstream analysis of genome-wide association study data.British journal of clinical pharmacology · 2025Review
- Translating pharmacogenomic sequencing data into drug response predictions-How to interpret variants of unknown significance.British journal of clinical pharmacology · 2025Review
- Deep Learning Prediction of Drug-Induced Liver Toxicity by Manifold Embedding of Quantum Information of Drug Molecules.Pharmaceutical research · 2025Article
- Genetic and Genomic Approaches to the Study of Drug-Induced Liver Injury.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques.Cell & bioscience · 2024Review
- Applications of 3D organoids in toxicological studies: a comprehensive analysis based on bibliometrics and advances in toxicological mechanisms.Archives of toxicology · 2024Review
- Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet.Pharmacological research · 2024Article
- Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling.Human genomics · 2023Article
- Applying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities.Briefings in bioinformatics · 2023Article
- Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case-control study.Diagnostic and prognostic research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 3 countries.
Masaru Koido *Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-0348-0666
Eri Kawakami *Organoid Medicine Project, T-CiRA Joint Program, Fujisawa, Kanagawa, Japan.
Junko FukumuraDepartment of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Yui NoguchiDepartment of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Momoko OhoriOrganoid Medicine Project, T-CiRA Joint Program, Fujisawa, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-4504-6032
Yasunori NioOrganoid Medicine Project, T-CiRA Joint Program, Fujisawa, Kanagawa, Japan.
Paola NicolettiDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Guruprasad P AithalNIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.ORCID http://orcid.org/0000-0003-3924-4830
Ann K DalyTranslational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Paul B WatkinsInstitute for Drug Safety Sciences, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Hisashi AnayamaDrug Safety Research and Evaluation, Takeda Pharmaceutical Company, Fujisawa, Kanagawa, Japan.
Yvonne DraganGlobal Discovery and Investigative Toxicology, Takeda Pharmaceutical Company, Cambridge, MA, USA.
Tadahiro ShinozawaOrganoid Medicine Project, T-CiRA Joint Program, Fujisawa, Kanagawa, Japan.
Takanori TakebeDepartment of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan. takanori.takebe@cchmc.org.ORCID http://orcid.org/0000-0002-6989-3041
Takeda (Japan) · JPYokohama City University · JPIcahn School of Medicine at Mount Sinai · USNewcastle University · GBNottingham University Hospitals NHS Trust · GBTakeda (United States) · USTokyo Medical and Dental University · JPUniversity of North Carolina at Chapel Hill · US
Funding
Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4MEngineering multi-organs in a dishDP2DK128799 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI TAKEBE, TAKANORI · 2020 to 2020
$2.3MModeling diabetes using an integrated plate systemUG3DK119982 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI LEE, MOO-YEAL, WELLS, JAMES M · 2018 to 2019
$1.7MMedical Research Council MC_PC_17173NIDDK NIH HHS DP2 DK128799NIDDK NIH HHS P30 DK078392NIDDK NIH HHS UG3 DK119982
Abstract
Drug-induced liver injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market; this is partially due to the inability to identify patients who are at risk
Indexed as
Multifactorial InheritancePolymorphism, Single NucleotideAllelesBenzofuransCase-Control StudiesCells, CulturedChemical and Drug Induced Liver InjuryCohort StudiesDatasets as TopicGene Expression ProfilingGene FrequencyGenetic Predisposition to DiseaseGenome-Wide Association StudyHepatocytesHumansMicroarray AnalysisBenzofuransSulfonesTAK-875
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.